PA21: A novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease

Clinical Nephrology

Volumn 74, Issue 1, 2010, Pages 4-11

  Geisser, P ^a   Philipp, E ^a  

^a Vifor (International) Inc   (Switzerland)

Author keywords

Iron; Iron based; PA21; Phosphate binder; Stabilized polynuclear iron(III) oxyhydroxide

Indexed keywords

CALCIFEDIOL; CALCITRIOL; FERRITIN; IRON 59; PA 21; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D; BIOLOGICAL MARKER; CHELATING AGENT; FERRIC ION; PA21 COMPOUND;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FLATULENCE; HUMAN; HYPERPHOSPHATEMIA; IRON BLOOD LEVEL; IRON OVERLOAD; IRON TRANSPORT; MALE; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHASE 1 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; RHINOPHARYNGITIS; TRANSFERRIN BLOOD LEVEL; UPPER ABDOMINAL PAIN; VITAMIN D METABOLISM; ADOLESCENT; BLOOD; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHELATING AGENTS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; VITAMIN D;

EID: 77954738634     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74004     Document Type: Article

References (22)

1. Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Semin Dial. 2007; 20: 286-294.
2. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 42: 1478-1483.
3. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002; 39: 695-701.
4. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, Cax PO4 product, and parathyroid hormone with cardiac mortality risk in chronic haemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138. (Pubitemid 32880350)
5. Young EW, Albert JM, Satayathum S, Goodkin DA Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.
6. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineralmetabolism and outcomes. J Am Soc Nephrol. 2004; 15: 770-779. (Pubitemid 38294808)
7. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrad DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16: 520-528. (Pubitemid 41725150)
8. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR. Association of serum phosphate with vascular and valcular calcification in moderateCKD. JAmSoc Nephrol. 2009; 20: 381-387.
9. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW; PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007; 22: 2909-2916.
10. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation. Am J Kidney Dis. 2003; 42 (Suppl): S1-S201.
11. Lacour B, Lucas A, AuchèreD, Ruellan N, de Serre Patey NM, Drüeke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005; 67: 1062-1069. (Pubitemid 41623331)
12. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 2005; 68: 2809-2813. (Pubitemid 43251027)
13. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D'Haese PC. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006; 21: 2217-2224.
14. Hutchison AJ, Barnett ME, Krause R, J, Siami GA, on behalf of the Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol. 2009; 71: 286-295.
15. Geisser P, Philipp E. Adsorbens für Phosphat aus wässerigem Medium, insbesondere für anorganisches oder nahrungsmittelgebundenes Phosphat aus Körperflüssigkeiten oder Nahrungsmitteln, das durch Kohlenhydrate und/oder Humussäure stabilisiertes polynukleares beta-Eisenhydroxid enthält. German Patent Application 1995 DE 195 47 356 A1.
16. Werner E, Kaltwasser JP. Judgment of measured values of intestinal iron absorption. Drug Res. 1987; 37: 116-121. (Pubitemid 17219722)
17. Cockcroft DW, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
18. Hergesell O, Ritz E. Stabilized Polynuclear Iron Hydroxide is an efficient, oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999; 14: 863-867. (Pubitemid 29155137)
19. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962; 51: 224-232.
20. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 (Suppl): 1-47.
21. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-- Beermann NM, Struyvenberg A, Marx JJM. Iron absorption in erythropoietin-treated hemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998; 13: 82-88. (Pubitemid 28033584)
22. Haillberg L, Hulthén L. Perspectives on iron absorption. Blood Cells Mol Dis. 2002; 29: 562-573.